19 May 2013
Keywords: Pfizer, Tofacitinib, Rheumatoid arthritis, Phase III
Article | 07 March 2011
Global drugs behemoth Pfizer (NYSE:PFE) says that tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor being studied ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 March 2011
17 May 2013
© 2013 thepharmaletter.com